文献速递神经肿瘤神经重症

幕上脑膜瘤术后早期癫痫的术前抗癫痫药物预防:单中心经验

Preoperative antiepileptic drug prophylaxis for early postoperative seizures in supratentorial meningioma: a single-center experience.
PubMed 文献 · J Neurooncol · 2022-04-17

本文回顾性分析2015至2021年在本机构接受组织学确诊的幕上凸面及矢状窦旁/大脑镰脑膜瘤切除术、术前无癫痫发作的517例患者,术后第一周内早期术后癫痫(EPS)发生率为5.8%(30/517)。多因素分析显示手术/内科并发症是EPS的唯一独立预测因子(OR 16.33,95%CI 7.07-37.7,P<0.001)。作者结合2011至2021年文献复习认为,抗癫痫药物预防可降低此类患者EPS发生率。

要点

  • 517例术前无癫痫发作的幕上凸面及矢状窦旁/大脑镰脑膜瘤患者中,EPS发生率为5.8%(30/517)。
  • 手术/内科并发症是EPS的唯一独立预测因子(OR 16.33,95%CI 7.07-37.7,P<0.001)。
  • 文献复习显示使用AED者EPS发生率为3.7%(47/1282),未使用者为6.2%(95/1525)。

核心结论

  • 作者认为,抗癫痫药物预防可降低术前无癫痫发作的凸面及矢状窦旁/大脑镰脑膜瘤患者的EPS发生率。
  • 避免术后并发症是预防EPS的重要手段。
  • 联合用药对控制反复EPS有显著效果。
  • 抗癫痫药物撤药时机根据临床症状和影像学表现评估。

研究设计与样本

  • 单中心回顾性研究,纳入2015至2021年在本机构接受治疗、组织学确诊为幕上凸面及矢状窦旁/大脑镰脑膜瘤的患者。
  • 共517例符合入选标准,评估临床与影像学资料,采用单因素和多因素回归分析。
  • 另对PubMed 2011至2021年发表的文献进行复习,共识别10项相关研究。

主要发现

  • 术后第一周内EPS见于30/517例(5.8%)。
  • 多因素分析显示手术/内科并发症是EPS的唯一独立预测因子(OR 16.33,95%CI 7.07-37.7,P<0.001)。
  • 根据癫痫发作频率(≤2次、>2次及癫痫持续状态)增加丙戊酸剂量并加用左乙拉西坦,EPS控制率分别为94.1%(16/17)和92.3%(12/13)。
  • 分别在2周和4-6周停用抗癫痫药物。
  • 文献复习中,术前无癫痫发作的幕上脑膜瘤患者使用AED者EPS发生率为3.7%(47/1282),未使用者为6.2%(95/1525);未使用AED的凸面及矢状窦旁/大脑镰脑膜瘤患者EPS发生率为9.0%(19/209)。

关键数值与推荐

  • EPS定义为术后第一周内发生的癫痫发作。
  • EPS控制率:94.1%(16/17)和92.3%(12/13),分别对应按癫痫发作频率调整治疗的两组情况。
  • 抗癫痫药物分别在2周和4-6周停用。
  • 文献复习中,使用AED者EPS发生率为3.7%(47/1282),未使用者为6.2%(95/1525)。
  • 文献复习中,未使用AED的凸面及矢状窦旁/大脑镰脑膜瘤患者EPS发生率为9.0%(19/209)。

临床怎么用

  • 作者认为,对术前无癫痫发作的凸面及矢状窦旁/大脑镰脑膜瘤患者,抗癫痫药物预防可降低EPS发生率。
  • 作者认为,避免术后并发症是预防EPS的重要手段。
  • 作者认为,联合用药对控制反复EPS有显著效果。
  • 抗癫痫药物撤药时机根据临床症状和影像学表现评估,原文报告分别在2周和4-6周停用。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Perioperative antiepileptic drug (AED) prophylaxis for early postoperative seizures (EPSs) in patients with supratentorial meningiomas without preoperative seizures is controversial. This paper discusses the incidence, risk factors, control rate and AED withdrawal indications of EPS in patients undergoing supratentorial convexity and parasagittal/falx meningioma resection without preoperative seizures. METHODS: Patients treated for a histologically confirmed supratentorial convexity and parasagittal/falx meningioma at the authors' institution between 2015 and 2021 were retrospectively examined. Clinical and imaging data were assessed. Variates were analyzed using univariate and multivariate regression analyses. A PubMed review of the literature published between 2011 and 2021 was performed. RESULTS: In total, 517 patients met the selection criteria. EPS (within the first postoperative week) was observed in 30/517 cases (5.8%). Multivariate analysis revealed that surgical/medical complications (OR 16.33, 95% CI 7.07-37.7, P < 0.001) were the only independent predictors of EPS. The dose of valproic was increased and levetiracetam was added based on the frequency of seizures (≤ 2, > 2 times and status epilepticus). EPS control rates were 94.1% (16/17) and 92.3% (12/13), respectively. AEDs were discontinued at 2 weeks and 4-6 weeks, respectively. The authors identified 10 relevant studies in the literature. Based on their review of the literature, the incidence of EPS was 3.7% (47/1282) with AED use and 6.2% (95/1525) without AED use patients in supratentorial meningiomas without preoperative seizures. The incidence of EPS was 9.0% (19/209) in patients without AED use with convexity and parasagittal/falx meningiomas without preoperative seizures. CONCLUSIONS: AED prophylaxis can reduce the incidence of EPS in patients with convexity and parasagittal/falx meningiomas without preoperative seizures. Avoiding postoperative complications is an important means to prevent EPS. Combined medication has a significant effect on controlling repeated EPS. The timing of AED withdrawal was evaluated according to the clinical symptoms and imaging findings.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Cai Q, Wu Y, Wang S, et al. Preoperative antiepileptic drug prophylaxis for early postoperative seizures in supratentorial meningioma: a single-center experience. J Neurooncol. 2022. PMID: 35434765. doi:10.1007/s11060-022-04009-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。